AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 156 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,032 | -77.6% | 1,173 | -74.4% | 0.00% | -75.0% |
| Q2 2023 | $129,763 | +227554.4% | 4,582 | +84.9% | 0.00% | +100.0% |
| Q1 2023 | $57 | +26.7% | 2,478 | +53.5% | 0.00% | 0.0% |
| Q4 2022 | $45 | -100.0% | 1,614 | -89.1% | 0.00% | -71.4% |
| Q3 2022 | $420,000 | +193.7% | 14,860 | +131.2% | 0.01% | +133.3% |
| Q2 2022 | $143,000 | -46.4% | 6,428 | -29.9% | 0.00% | 0.0% |
| Q1 2022 | $267,000 | -37.8% | 9,167 | -29.8% | 0.00% | -57.1% |
| Q4 2021 | $429,000 | +124.6% | 13,063 | +215.4% | 0.01% | +40.0% |
| Q3 2021 | $191,000 | +9.1% | 4,142 | +30.2% | 0.01% | 0.0% |
| Q2 2021 | $175,000 | +124.4% | 3,181 | +110.5% | 0.01% | +400.0% |
| Q1 2021 | $78,000 | -85.1% | 1,511 | -87.5% | 0.00% | -93.8% |
| Q4 2020 | $522,000 | +255.1% | 12,054 | +186.4% | 0.02% | +700.0% |
| Q3 2020 | $147,000 | +258.5% | 4,209 | +447.3% | 0.00% | 0.0% |
| Q2 2020 | $41,000 | -79.4% | 769 | -81.6% | 0.00% | -88.2% |
| Q4 2019 | $199,000 | +804.5% | 4,171 | +528.2% | 0.02% | +750.0% |
| Q3 2019 | $22,000 | +69.2% | 664 | +159.4% | 0.00% | +100.0% |
| Q2 2019 | $13,000 | +160.0% | 256 | +271.0% | 0.00% | – |
| Q1 2019 | $5,000 | +400.0% | 69 | +331.2% | 0.00% | – |
| Q4 2018 | $1,000 | -98.0% | 16 | -97.4% | 0.00% | -100.0% |
| Q1 2018 | $51,000 | +1175.0% | 626 | +820.6% | 0.00% | +300.0% |
| Q4 2017 | $4,000 | -55.6% | 68 | -62.2% | 0.00% | 0.0% |
| Q2 2017 | $9,000 | -91.3% | 180 | -92.8% | 0.00% | -90.9% |
| Q4 2016 | $103,000 | +202.9% | 2,487 | +291.0% | 0.01% | +266.7% |
| Q3 2016 | $34,000 | +240.0% | 636 | +148.4% | 0.00% | +200.0% |
| Q1 2016 | $10,000 | -63.0% | 256 | -38.8% | 0.00% | -75.0% |
| Q4 2015 | $27,000 | -47.1% | 418 | -21.7% | 0.00% | -33.3% |
| Q1 2015 | $51,000 | +292.3% | 534 | +356.4% | 0.01% | +500.0% |
| Q4 2014 | $13,000 | +62.5% | 117 | -5.6% | 0.00% | 0.0% |
| Q3 2014 | $8,000 | -86.9% | 124 | -92.0% | 0.00% | -87.5% |
| Q1 2014 | $61,000 | +60.5% | 1,546 | +14.3% | 0.01% | +100.0% |
| Q3 2013 | $38,000 | – | 1,353 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |